WARREN, N.J., Oct. 11, 2024 — Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers, plans to share its $1B+ revenue potential, a reflection of the company’s novel business approach.
“In the current market reality, Tevogen Bio’s unique, faster, and cost-efficient drug development model has the potential to serve as a blueprint to ensure sustainable medical innovation for years to come. With over three decades of experience in the biopharma industry, Tevogen’s projected multi-billion-dollar revenue reassures me of the company’s strong business fundamentals and its bold, patient-centric drug development strategy, aimed at addressing some of the most pressing health conditions impacting large patient populations,” remarked Ryan Saadi, MD, MPH, Founding CEO, and 2023 Nobel Nominee.
Pipeline
-
TVGN 489:
-
Treatment of SARS-CoV-2 infection in patients with B cell hematologic cancer
-
Treatment of SARS-CoV-2 infection in patients with other cancers
-
SARS-CoV-2 infection in patients under treatment for rheumatoid arthritis
-
SARS-CoV-2 infection in patients under treatment for psoriatic arthritis
-
Treatment of Long COVID
-
-
TVGN 920: Cervical cancer prevention
-
TVGN 930: EBV-associated lymphomas
-
TVGN 960: Mouth and throat cancer
-
TVGN 601: Multiple sclerosis